Recurrent seizure at 6 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 12 months · children with febrile seizures
Intermittent oral diazepam showed no clear difference in recurrent seizure at 12 months compared with intermittent oral clobazam (low certainty).
1 finding from 1 review
Recurrent seizure at 18 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 24 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 36 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 48 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 60 months or greater · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maximum voluntary jaw opening (mm), change from baseline · Adults (>18 years) with temporomandibular joint osteoarthritis (TMJ OA) diagnosed by RDC/TMD or compatible criteria
Glucosamine sulfate (oral) showed no clear difference in maximum voluntary jaw opening (mm), change from baseline compared with ibuprofen (oral); GRADE not reported.
1 finding from 1 review
Reported pain (mm on VAS), change from baseline · Adults (>18 years) with temporomandibular joint osteoarthritis (TMJ OA) diagnosed by RDC/TMD or compatible criteria
Glucosamine sulfate (oral) showed no clear difference in reported pain (mm on VAS), change from baseline compared with ibuprofen (oral); GRADE not reported.
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Adults (>18 years) with temporomandibular joint osteoarthritis (TMJ OA) diagnosed by RDC/TMD or compatible criteria
Glucosamine sulfate (oral) showed no clear difference in brief Pain Inventory (BPI) - pain intensity, change from baseline compared with ibuprofen (oral); GRADE not reported.
1 finding from 1 review
Pain-free maximum jaw opening (mm), change from baseline · Adults (>18 years) with temporomandibular joint osteoarthritis (TMJ OA) diagnosed by RDC/TMD or compatible criteria
Glucosamine sulfate (oral) showed no clear difference in pain-free maximum jaw opening (mm), change from baseline compared with ibuprofen (oral); GRADE not reported.
1 finding from 1 review
Brief Pain Inventory (BPI) - pain interference, change from baseline · Adults (>18 years) with temporomandibular joint osteoarthritis (TMJ OA) diagnosed by RDC/TMD or compatible criteria
Glucosamine sulfate (oral) showed no clear difference in brief Pain Inventory (BPI) - pain interference, change from baseline compared with ibuprofen (oral); GRADE not reported.
1 finding from 1 review
Pain during function (proportion without significant improvement) · Adults (>18 years) with temporomandibular joint osteoarthritis (TMJ OA) diagnosed by RDC/TMD or compatible criteria
Glucosamine sulfate (oral) led to lower pain during function (proportion without significant improvement) compared with ibuprofen (oral); GRADE not reported.
1 finding from 1 review
Six participants in the glucosamine group did not experience significant improvement in TMJ pain compared with seven in the ibuprofen group (Analysis 3.1); Fisher's exact test P = 0.73 (not significant, per the authors).
1 study · 45 participants
GRADE not reported
Adverse events: thromboses · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes adverse events: thromboses compared with oral steroids alone (very low certainty).
1 finding from 1 review
Gastrointestinal bleeding · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes adverse events: gastrointestinal bleeding compared with oral steroids alone (very low certainty).
1 finding from 1 review
Complete remission · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes complete remission Time frame: 2 to 28 months compared with oral steroids alone (very low certainty).
1 finding from 1 review
Complete or partial remission · minimal change disease in adults with nephrotic syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes relapse during compared with oral steroids alone (very low certainty).
1 finding from 1 review
Recurrent seizure at 6 months · children with febrile seizures
1 finding from 1 review
Recurrent seizure at 12 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found